Boehringer Ingelheim International GmbHPrivate▲ Positive
Demandrelevance
Strong U.S. demand for JARDIANCE and successful new product launches drove 16.2% net sales growth.
Boehringer Ingelheim reported a 16.2 percent increase in group net sales to 15.8 billion euros for the first half of 2026, driven by strong U.S. demand for JARDIANCE and successful new product launches. Human Pharma sales grew 20.1 percent to 13.1 billion euros, with JARDIANCE alone contributing 5.7 billion euros, while Animal Health sales edged up 0.4 percent to 2.6 billion euros. The company highlighted the U.S. uptake of recently launched JASCAYD for pulmonary fibrosis and HERNEXEOS for lung cancer, and noted positive Phase III data for survodutide in obesity and metabolic health. Boehringer also advanced its pipeline with three new Phase III oncology trials and five compounds entering clinical development.
Strong U.S. demand for JARDIANCE and successful new product launches drove 16.2% net sales growth.